These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

317 related articles for article (PubMed ID: 35765634)

  • 1. A Review of Systemic Biologics and Local Immunosuppressive Medications in Uveitis.
    S Mehta N; Emami-Naeini P
    J Ophthalmic Vis Res; 2022; 17(2):276-289. PubMed ID: 35765634
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Update on the use of systemic biologic agents in the treatment of noninfectious uveitis.
    Pasadhika S; Rosenbaum JT
    Biologics; 2014; 8():67-81. PubMed ID: 24600203
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Immunosuppressive Treatment of Non-infectious Uveitis: History and Current Choices.
    Zhao C; Zhang M
    Chin Med Sci J; 2017 Apr; 32(1):48-61. PubMed ID: 28399985
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Initial evaluation of subcutaneous daclizumab treatments for noninfectious uveitis: a multicenter noncomparative interventional case series.
    Nussenblatt RB; Peterson JS; Foster CS; Rao NA; See RF; Letko E; Buggage RR
    Ophthalmology; 2005 May; 112(5):764-70. PubMed ID: 15878055
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Intravitreal Sirolimus for the Treatment of Noninfectious Uveitis: Evolution through Preclinical and Clinical Studies.
    Nguyen QD; Merrill PT; Sepah YJ; Ibrahim MA; Banker A; Leonardi A; Chernock M; Mudumba S; Do DV
    Ophthalmology; 2018 Dec; 125(12):1984-1993. PubMed ID: 30060978
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Non-anti TNFα biologic agents for noninfectious uveitis associated with systemic inflammatory diseases: a systematic review.
    Bitossi A; Mattioli I; Bettiol A; Palermo A; Malandrino D; Bacherini D; Virgili G; Giansanti F; Vannozzi L; Silvestri E
    Expert Rev Clin Immunol; 2023 May; 19(5):549-560. PubMed ID: 36939549
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Recent advances in uveitis therapy: focus on selected phase 2 and 3 clinical trials.
    Thng ZX; Bromeo AJ; Mohammadi SS; Khatri A; Tran ANT; Akhavanrezayat A; T T Than N; Nguyen KS; Yoo WS; Mobasserian A; Or CCM; Nguyen QD
    Expert Opin Emerg Drugs; 2023 Dec; 28(4):297-309. PubMed ID: 38129984
    [TBL] [Abstract][Full Text] [Related]  

  • 8. An Observational Study in the Real Clinical Practice of the Treatment of Noninfectious Uveitis.
    Esteban-Ortega M; Steiner M; Andreu-Vázquez C; Thuissard-Vasallo I; Díaz-Rato A; Muñoz-Fernández S
    J Clin Med; 2024 Feb; 13(5):. PubMed ID: 38592203
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Perspectives for immunotherapy in noninfectious immune mediated uveitis.
    Touhami S; Gueudry J; Leclercq M; Touitou V; Ghembaza A; Errera MH; Saadoun D; Bodaghi B
    Expert Rev Clin Immunol; 2021 Sep; 17(9):977-989. PubMed ID: 34264142
    [No Abstract]   [Full Text] [Related]  

  • 10. Systemic immunosuppressive therapies for uveitis in developing countries.
    Agrawal H; Doan H; Pham B; Khosla A; Babu M; McCluskey P; Nguyen QD; Sangwan V; Reddy S; Sawhney S; Tyagi M
    Indian J Ophthalmol; 2020 Sep; 68(9):1852-1862. PubMed ID: 32823402
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A comprehensive review and update on the biologic treatment of adult noninfectious uveitis: part II.
    Lee K; Bajwa A; Freitas-Neto CA; Metzinger JL; Wentworth BA; Foster CS
    Expert Opin Biol Ther; 2014 Nov; 14(11):1651-66. PubMed ID: 25226284
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Dexamethasone for ocular inflammation.
    Saraiya NV; Goldstein DA
    Expert Opin Pharmacother; 2011 May; 12(7):1127-31. PubMed ID: 21457057
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Ocular sarcoidosis].
    Springer-Wanner C; Brauns T
    Z Rheumatol; 2017 Jun; 76(5):391-397. PubMed ID: 28516270
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Emerging drugs for the treatment of noninfectious uveitis.
    Pleyer U; Pohlmann D; Kardeş E; Poddubnyy D; Rademacher J
    Expert Opin Emerg Drugs; 2019 Sep; 24(3):173-190. PubMed ID: 31498689
    [No Abstract]   [Full Text] [Related]  

  • 15. Side-effects of anti-inflammatory therapy in uveitis.
    Uchiyama E; Papaliodis GN; Lobo AM; Sobrin L
    Semin Ophthalmol; 2014; 29(5-6):456-67. PubMed ID: 25325874
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Noninfectious uveitis: strategies to optimize treatment compliance and adherence.
    Dolz-Marco R; Gallego-Pinazo R; Díaz-Llopis M; Cunningham ET; Arévalo JF
    Clin Ophthalmol; 2015; 9():1477-81. PubMed ID: 26316689
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Noninfectious immune-mediated uveitis and ocular inflammation.
    Pan J; Kapur M; McCallum R
    Curr Allergy Asthma Rep; 2014 Jan; 14(1):409. PubMed ID: 24338488
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A systematic review of biologics for the treatment of noninfectious uveitis.
    Takeuchi M
    Immunotherapy; 2013 Jan; 5(1):91-102. PubMed ID: 23256801
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Uveitis, the Comparison of Age-Related Macular Degeneration Treatments Trials (CATT), and intravitreal biologics for ocular inflammation.
    Yeh S; Albini TA; Moshfeghi AA; Nussenblatt RB
    Am J Ophthalmol; 2012 Sep; 154(3):429-435.e2. PubMed ID: 22898344
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Recommendation of using systemic anti-tumor necrosis factor-alpha for the treatment of noninfectious uveitis in Taiwan.
    Hwang DK; Hwang YS; Tsai ML; Lin CJ; Chan WC; Chang YC; Chen DY; Hsieh TY; Sheu SJ; Lin CP
    Taiwan J Ophthalmol; 2018; 8(3):117-120. PubMed ID: 30294525
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.